Hyoscine Can Be Given to Pediatric Patients
Yes, hyoscine can be safely administered to pediatric patients, with FDA-approved formulations available for children as young as 2 years of age, and evidence supporting off-label use in even younger infants. 1
FDA-Approved Dosing
The FDA label for hyoscyamine sulfate (a form of hyoscine) provides clear pediatric dosing 1:
- Children 2 to under 12 years: ½ to 1 tablet (0.0625-0.125 mg) every 4 hours as needed, not exceeding 6 tablets in 24 hours
- Children 12 years and older: 1 to 2 tablets (0.125-0.25 mg) every 4 hours as needed, not exceeding 12 tablets in 24 hours
The tablets may be taken sublingually, orally, or chewed, providing flexibility in administration for different age groups.
Evidence Supporting Pediatric Use
Hyoscine Butylbromide (Buscopan)
The most comprehensive recent evidence comes from a 2025 systematic review demonstrating safety across thousands of pediatric patients, including those younger than 6 years 2. This review found:
- Studies included children as young as 2 days of age
- No safety concerns identified across approved and off-label indications
- Well-tolerated with minimal adverse effects
A 2020 randomized controlled trial in children aged 8-17 years with colicky abdominal pain showed hyoscine butylbromide was equivalent to acetaminophen for pain relief, with adverse effects occurring in 27.6% (mostly mild) and no serious adverse events 3.
Scopolamine (Transdermal)
For drooling and secretion management, a 2026 case series demonstrated safe and effective use of transdermal scopolamine ointment in pediatric brain tumor patients, with objective improvements in respiratory symptoms and no severe adverse events 4. Additional case reports support its use in mechanically ventilated children via gastrostomy without complications 5.
Clinical Applications in Pediatrics
Hyoscine has proven efficacy in multiple pediatric scenarios:
- Abdominal pain/cramping: Equivalent to acetaminophen 3
- Esophageal foreign body: 82% success rate for lower esophageal sphincter relaxation 6
- Excessive salivation/drooling: Effective in neurologically impaired children 4, 5
- Procedural use: Evidence supports use in anesthesia and diagnostic procedures 2
Important Caveats
- Age restrictions vary by formulation: FDA-approved oral forms are for ≥2 years, but off-label use in younger infants is supported by evidence
- Anticholinergic effects: Monitor for urinary retention, dry mouth, blurred vision, though these are generally mild
- Contraindication: Avoid in myasthenia gravis patients (though hyoscine butylbromide may be safer due to quaternary structure limiting CNS penetration) 7
- Route matters: Hyoscine butylbromide has poor oral bioavailability but works well for GI indications; scopolamine has better systemic absorption
The safety profile across age ranges from neonates to adolescents is well-established, making hyoscine a viable option for multiple pediatric indications when dosed appropriately.